Teladoc price target lowered to $33 from $36 at Citi

Citi analyst Daniel Grosslight lowered the firm’s price target on Teladoc to $33 from $36 and keeps a Neutral rating on the shares. In 2022, the company faced significant headwinds in its BetterHelp and chronic care businesses, says the analyst, who does not see these headwinds abating "anytime soon." As such, Teladoc will continue to face slowing growth in 2023, Grosslight tells investors in a research note.